The biologics development and approval process for pharmaceutical companies around the world is typically long and complex, which increases the risk of inaccurately forecasting demand
By Steve Lam, Senior Vice President, Patheon’s Biologics Unit
Advertisement
Articles by By Steve Lam, Senior Vice President, Patheon’s Biologics Unit
Advertisement
Latest Updated Articles
- Dealing with biologics production uncertainty
Published: July 6th 2016 | Updated:
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
How Healthcare Organizations Can Balance Federal and State AI Regulations
2
AstraZeneca Expands Texas Manufacturing Facility to Double Production of Hyperkalemia Drug
3
United States Delays Tariffs on Singapore’s Pharma Exports Amid Ongoing Trade Negotiations
4
Pharma Pulse: FDA Approves One-Minute HIV Test, US Delays Pharma Tariffs, and CVS Acquires 600 Rite Aid Stores
5
